// App-Quantinova.ai

e16578 : Cabozantinib in metastatic renal cell carcinoma (mRCC): Real world experience from the UK.

Researchers

Presenter

  • Alfonso Gomez de Liano

Principal Investigators

  • Balaji Venugopal

  • Kate Fife

  • Luma Khasti

  • Stefan N. Symeonides

  • Claire Pettinger

  • Thomas Powles

  • Sarah Maria Rudman

  • Naveen Vasudev

  • Ekaterini Boleti

Medical Centers

  • Bart's Cancer Institute, London, United Kingdom

  • Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

  • Edinburgh Cancer Research Center, University of Edinburgh, Edinburgh, United Kingdom

  • University of Edinburgh, Glasgow, United Kingdom

  • Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

  • Guy's Hospital, London, United Kingdom

  • St James Hospital, Leeds, United Kingdom

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Cabozantinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved